Marinomed Biotech AG
MARI.VI · VIE
6/30/2025 | 3/31/2025 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | – | €0 | €0 | €0 |
| % Growth | – | 278.3% | 134.1% | – |
| Cost of Goods Sold | – | €0 | €0 | €0 |
| Gross Profit | – | €0 | €0 | -€0 |
| % Margin | – | 0% | 39.9% | -204.4% |
| R&D Expenses | – | €0 | €0 | €0 |
| G&A Expenses | – | €0 | €0 | €0 |
| SG&A Expenses | – | €0 | €0 | -€0 |
| Sales & Mktg Exp. | – | €0 | €0 | €0 |
| Other Operating Expenses | – | -€0 | €0 | -€0 |
| Operating Expenses | – | -€0 | €0 | €0 |
| Operating Income | – | €0 | -€0 | -€0 |
| % Margin | – | 340.3% | -78.1% | -254.6% |
| Other Income/Exp. Net | – | -€0 | -€0 | -€0 |
| Pre-Tax Income | – | €0 | -€0 | -€0 |
| Tax Expense | – | €0 | €0 | €0 |
| Net Income | – | €0 | -€0 | -€0 |
| % Margin | – | 338.7% | -504.2% | -288.8% |
| EPS | – | 12.44 | -5.65 | -1.39 |
| % Growth | – | 320.2% | -306.5% | – |
| EPS Diluted | – | 12.44 | -5.65 | -1.39 |
| Weighted Avg Shares Out | – | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | – | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | €0 | €0 | €0 |
| Interest Expense | – | €0 | €0 | €0 |
| Depreciation & Amortization | – | €0 | €0 | €0 |
| EBITDA | – | €0 | -€0 | -€0 |
| % Margin | – | 340.3% | -70.3% | -176.4% |